CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market Definition and Scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2017

3.3. Top player positioning, 2017
3.4. Porter's five forces analysis
3.5. Government Regulations
3.6. Market Dynamics

3.6.1. Drivers

3.6.1.1. Surge in research and development activities in healthcare
3.6.1.2. Rise in adoption of vitro model
3.6.1.3. Increase in stringency of regulatory authorities concerning public healthcare welfare
3.6.1.4. Surge in adoption of early toxicity testing

3.6.2. Restraints

3.6.2.1. Limitations of preclinical testing

3.6.3. Opportunities

3.6.3.1. Technological advancement in the field of early toxicity testing

3.6.4. Impact Analyses

CHAPTER 4: EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

4.1. Overview

4.1.1. Market size and forecast

4.2. In Vivo

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by country

4.3. In Vitro

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by country
4.3.3. In Vitro Early Toxicity Testing Market, By Assay

4.3.3.1. Enzyme toxicity assays

4.3.3.1.1. Market size and forecast

4.3.3.2. Bacterial toxicity assays

4.3.3.2.1.1. Market size and forecast

4.3.3.3. Cell-Based ELISA and Western Blots

4.3.3.3.1.1. Market size and forecast

4.3.3.4. Tissues Culture Assays

4.3.3.4.1.1. Market size and forecast

4.3.3.5. Receptor Binding Assays

4.3.3.5.1.1. Market size and forecast

4.3.3.6. Other Assays

4.3.3.6.1.1. Market size and forecast

4.3.4. In Vitro Early Toxicity Testing Market, By Toxicity End-Points

4.3.4.1. Dermal Toxicity

4.3.4.1.1.1. Market size and forecast
4.3.4.1.1.2. Market size and forecast, by end user

4.3.4.2. Systemic toxicity

4.3.4.2.1.1. Market size and forecast
4.3.4.2.1.2. Market size and forecast, by end user

4.3.4.3. Carcinogenicity

4.3.4.3.1.1. Market size and forecast

4.3.4.4. Ocular toxicity

4.3.4.4.1.1. Market size and forecast
4.3.4.4.1.2. Market size and forecast, by end user

4.3.4.5. Skin sensitization and irritation

4.3.4.5.1.1. Market size and forecast

4.3.4.6. Genotoxicity

4.3.4.6.1.1. Market size and forecast

4.3.4.7. Neurotoxicity

4.3.4.7.1.1. Market size and forecast

4.3.4.8. Organ toxicity

4.3.4.8.1.1. Market size and forecast

4.3.4.9. Other toxicity endpoints

4.3.4.9.1.1. Market size and forecast

4.4. In Silico

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by country

CHAPTER 5: EUROPE EARLY TOXICITY TESTING MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Medical

5.2.1. Market size and forecast, by type

5.2.1.1. Examination

5.2.1.1.1. Market size and forecast

5.2.1.2. Surgical

5.2.1.2.1. Market size and forecast

5.2.2. Market size and forecast, by country

5.3. Non-Medical

5.3.1. Market size and forecast, by type

5.3.1.1. Food services

5.3.1.1.1. Market size and forecast

5.3.1.2. Clean Room

5.3.1.2.1. Market size and forecast

5.3.1.3. Industrial

5.3.1.3.1. Market size and forecast

5.3.2. Market size and forecast, by country

CHAPTER 6: EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

6.1. Overview

6.1.1. Market size and forecast

6.2. Pharmaceutical Industry

6.2.1. Market size and forecast, by country

6.3. Diagnostics Industry

6.3.1. Market size and forecast, by country

6.4. Food Industry

6.4.1. Market size and forecast, by country

6.5. Chemicals Industry

6.5.1. Market size and forecast, by country

6.6. Cosmetic Industry

6.6.1. Market size and forecast, by country

6.7. Other Industries

6.7.1. Market size and forecast, by country

CHAPTER 7: EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY

7.1. Overview

7.1.1. Key market trends, growth factors, and opportunities
7.1.2. Market size and forecast, by country

7.1.2.1. Germany

7.1.2.1.1. Germany market size and forecast, by technique
7.1.2.1.2. Germany market size and forecast, by application
7.1.2.1.3. Germany market size and forecast, by end user

7.1.2.2. France

7.1.2.2.1. France market size and forecast, by technique
7.1.2.2.2. France market size and forecast, by application
7.1.2.2.3. France market size and forecast, by end user

7.1.2.3. UK

7.1.2.3.1. UK market size and forecast, by technique
7.1.2.3.2. UK market size and forecast, by application
7.1.2.3.3. UK market size and forecast, by end user

7.1.2.4. Rest of Europe

7.1.2.4.1. Rest of Europe market size and forecast, by technique
7.1.2.4.2. Rest of Europe market size and forecast, by application
7.1.2.4.3. Rest of Europe market size and forecast, by end user

7.1.3. Market size and forecast, by technique
7.1.4. Market volume and forecast, by application
7.1.5. Market volume and forecast, by end user

CHAPTER 8: COMPANY PROFILES, KEY MANUFACTURERS

8.1. Agilent Technologies, Inc.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product type Portfolio
8.1.5. Business performance

8.2. General Electric Company (GE Healthcare)

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance

8.3. Danaher Corporation (Beckman Coulter, Inc.)

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product type portfolio
8.3.5. Business performance

8.4. Evotec AG (Cyprotex)

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance

8.5. Bioanalytical Systems, Inc.

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance

8.6. BRUKER CORPORATION

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance

8.7. PerkinElmer Inc.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance

8.8. Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.)

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio
8.8.5. Business performance

8.9. The Jackson Laboratory



8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Product Portfolio
8.9.4. Business performance

8.10. Thermo Fisher Scientific, Inc.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. BUSINESS PERFORMANCE